Light Sidamet Tablet 50/850 Milligrams
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Light Pharmtech Co., Ltd.
MFDS item code 202200486 · Approved 2022.01.28
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to more effectively control blood sugar in patients with type 2 diabetes. It is especially administered as an adjunct when blood sugar control is difficult with diet and exercise alone. It can be used in patients who have no prior experience with diabetic drug therapy or when monotherapy is insufficient. Additionally, it is administered when blood sugar control is inadequate with either metformin or sitagliptin monotherapy, or to replace the combination therapy with these two medications. In cases where blood sugar control is challenging, it may be combined with sulfonylureas, thiazolidinediones, insulin, etc. to enhance treatment efficacy. In summary, this medication effectively improves blood sugar control when used alone or in combination with various diabetes treatments.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Should Not Receive This Medicine). 2. Patients treated with metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral blood glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Receive This Medicine).
This medication contains sitagliptin and metformin, which help in blood sugar control. There are several precautions to be aware of: First, since there is a risk of hypersensitivity, if symptoms like skin rash, urticaria, or breathlessness occur, discontinue use immediately and consult a doctor. Secondly, there is a risk of acute pancreatitis; therefore, if symptoms such as abdominal pain, nausea, or vomiting occur, inform a doctor immediately. Thirdly, due to the metformin component, there is a rare but potentially fatal side effect called lactic acidosis, so if sudden onset breathlessness, muscle pain, fatigue, or abdominal pain occurs, seek treatment immediately. Fourthly, patients with poor kidney function or those experiencing severe infections or dehydration should not take this medication. Fifthly, this medication should be temporarily discontinued prior to examinations using iodine contrast agents, and can be resumed only after confirming normal kidney function after the examination. Sixthly, pregnant or potentially pregnant women, as well as nursing mothers, should not take this medication. Seventhly, this medication can cause hypoglycemia; therefore, caution should be exercised with irregular meals or vigorous exercise, and patients should closely monitor their blood sugar levels when taken together with other hypoglycemic agents as hypoglycemia symptoms may be more pronounced. Eighthly, patients with liver dysfunction should also avoid taking this medicine and should have regular blood tests and kidney function tests. Lastly, excessive alcohol intake during treatment should be avoided as it may increase the risk of lactic acidosis.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid air and moisture, ideally at room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the medication for a longer period.
Pink oval film-coated tablet with '715' engraved on one side
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Light Pharmtech Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.